Although targeted therapies, such as BCL-2, FLT3, and IDH inhibitors, as well as CD33 antibody–drug conjugates and oral hypomethylating agents, have shown significant benefits in the treatment of AML [64], targeted therapy for AML remains challenging because LSC could not get effective targeted clearance by currently available treatments. This evidence concerns the gene CD33 and acute myeloid leukemia.